LB Pharmaceuticals INC
SEC CIK 1691082 · LBRX · last insider filing 2026-06-05
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Ruffolo Robert R | Director | filed 2025 - 2026 |
| Garland J. Scott | Director | filed 2025 - 2026 |
| Nussbaum Ran | Director | filed 2025 - 2026 |
| Hemrajani Rekha | Director | filed 2025 - 2026 |
| Kane William P Jr | Director | filed 2025 - 2026 |
| Lenz Robert A. | Director | filed 2026 - 2026 |
| Luse Rebecca | Director | filed 2025 - 2026 |
| Prensky Zachary | Director | filed 2025 - 2025 |
| Turner Heather D | Director · Chief Executive Officer | filed 2025 - 2025 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Pai Panandiker Kaya Kamlesh | Chief Commercial Officer | filed 2025 - 2025 |
| Panoff Marc L | Senior Vice President, Finance | filed 2025 - 2025 |
| Soffer Gad | Chief Business Officer | filed 2025 - 2025 |
| Eramo Anna | Chief Medical Officer | filed 2025 - 2025 |
| Silva Richard Anthony | SVP, Technical Operations | filed 2025 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.